



Published as: *Immunity*. 2011 August 26; 35(2): 249–259.

CD8 α ⁺ dendritic cells are the critical source of interleukin-12 that controls acute infection by *Toxoplasma gondii* tachyzoites

Mona Mashayekhi¹, Michelle M. Sandau¹, Ildiko R. Dunay², Eva M. Frickel⁴, Asis Khan², Romina S. Goldszmid^{5,6}, Alan Sher⁵, Hidde L. Ploegh⁴, Theresa L. Murphy¹, L. David Sibley², and Kenneth M. Murphy^{1,3}

¹Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110 USA

²Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110 USA

³Howard Hughes Medical Institute, Washington University School of Medicine, Saint Louis, MO 63110 USA

⁴Whitehead Institute for Biomedical Research, Cambridge, MA 02142 USA

⁵Immunobiology section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 USA

⁶Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702 USA

Summary

CD8 α ⁺ dendritic cells (DCs) are important *in vivo* for cross-presentation of antigens derived from intracellular pathogens and tumors. Additionally, secretion of interleukin-12 (IL-12) by CD8 α ⁺ DCs suggests a role for these cells in response to *Toxoplasma gondii* antigens, although it remains unclear whether these cells are required for protection against *T. gondii* infection. Towards this goal, we examined *T. gondii* infection of *Batf3*^{-/-} mice, which selectively lack only lymphoid-resident CD8 α ⁺ DCs and related peripheral CD103⁺ DCs. *Batf3*^{-/-} mice were extremely susceptible to *T. gondii* infection, with decreased production of IL-12 and interferon- γ . IL-12 administration restored resistance in *Batf3*^{-/-} mice, and mice in which IL-12 production was ablated only from CD8 α ⁺ DCs failed to control infection. These results reveal that the function of CD8 α ⁺ DCs extends beyond a role in cross-presentation and includes a critical role for activation of innate immunity through IL-12 production during *T. gondii* infection.

© 2011 Elsevier Inc. All rights reserved.

Correspondence to: Kenneth M. Murphy; Tel #: (314) 362-2009; Fax #: (314) 747-4888; KMurphy@pathology.wustl.edu. M.M. Sandau's present address is: AFB International, Saint Charles, MO 63004 USA; I.R. Dunay's present address is: Institute of Medical Microbiology, Otto-von-Guericke University, Magdeburg, Germany; E.M. Frickel's present address is: MRC National Institute for Medical Research, London, United Kingdom

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors have no conflicting financial interests.

Introduction

Although cell-mediated immunity is critical for defense against the intracellular pathogen *Toxoplasma gondii*, the precise cells responsible for initiating the protective innate and adaptive responses have been difficult to identify. *Toxoplasma gondii* is an intracellular protozoan parasite whose elimination requires production of interferon- γ (IFN γ) that activates various cell-intrinsic anti-parasitic defense pathways within infected cells (Yap et al., 2006). The production of IFN γ in *T. gondii* infection is dependent on interleukin-12 (IL-12) (Gazzinelli et al., 1993), and while a number of studies have identified cells capable of producing IL-12 in response to *T. gondii*, none has unambiguously identified the cellular source of IL-12 in *T. gondii* infection relevant to protection *in vivo*. Several different cells have been proposed to be important sources of IL-12 during *T. gondii* infection, including neutrophils (Bliss et al., 1999; Bliss et al., 2000), macrophages (Gazzinelli et al., 1994; Robben et al., 2004), plasmacytoid dendritic cells (pDCs) (Pepper et al., 2008), conventional dendritic cells (cDCs) (Liu et al., 2006), and the subset of conventional dendritic cells expressing CD8 α (Reis e Sousa et al., 1997).

Neutrophils have been reported to produce IL-12 *in vitro* in response to *T. gondii* antigens, but it is unlikely that they are required for protective immunity to *T. gondii* *in vivo*. Neutrophils are rapidly recruited to the peritoneum after infection with high doses of virulent strains of *T. gondii*, where they co-stain for IL-12 by microscopy (Bliss et al., 1999; Bliss et al., 2000). However, influx of neutrophils is not observed following oral infection with low virulence isolates, mimicking natural routes of infection (Dunay et al., 2008). Initial *in vivo* studies in which neutrophils were depleted using the Ly6C-specific antibody RB6-8C5 suggested a crucial function for neutrophils in protective immunity against *T. gondii* (Sayles and Johnson, 1996; Bliss et al., 2001; Schariton-Kersten et al., 1997b). However, inflammatory monocytes expressing the same marker Ly6C were later identified (Mordue and Sibley, 2003; Serbina and Pamer, 2006), and all studies conducted with RB6-8C5 were confounded by dual elimination of both neutrophils and inflammatory monocytes. In a more recent study, Dunay et al. depleted only neutrophils *in vivo* using the Ly-6G specific monoclonal antibody 1A8, and demonstrated that specific ablation of neutrophils does not increase the susceptibility of mice to *T. gondii* infection or alter serum concentrations of IL-12 (Dunay et al., 2010). These recent data argue that neutrophils are less likely to be a critical *in vivo* source of IL-12 that is relevant to protection during *T. gondii* infection.

Several cells other than neutrophils are viable candidates as an important source of IL-12 in providing protective immunity to *T. gondii*, including monocytes and macrophages. Gazzinelli et al. first demonstrated that thioglycolate elicited peritoneal macrophages produce IL-12 in response to *in vitro* stimulation with soluble tachyzoite antigen (STAg) (Gazzinelli et al., 1994). In addition, IL-12 mRNA could be detected in peritoneal exudate cells (PECs) of mice infected with *T. gondii*, although individual cell types from the exudate were not distinguished in this study. Low density splenocytes as well as bone marrow-derived macrophages (BMMs) were also capable of producing IL-12 in response to *in vitro* *T. gondii* infection (Robben et al., 2004). These studies demonstrate that activated or *in vitro* derived macrophages can produce IL-12, but do not demonstrate an *in vivo* function for these cells. In a model of oral infection, Gr1⁺ inflammatory monocytes that are recruited to the intestine express IL-12 *in vivo* (Dunay et al., 2008), although a functional requirement for IL-12 production by these cells was not demonstrated. pDCs can also produce IL-12 in response to *in vitro* infection by *T. gondii* (Pepper et al., 2008), although in this study, only *in vitro* generated bone-marrow derived pDCs were examined, and an *in vivo* requirement for pDCs during *T. gondii* infection was not tested. Thus, while various monocyte, macrophage, and pDC populations can produce IL-12 in response to *T. gondii*, their

importance as a source of IL-12 for *in vivo* protection against *T. gondii* infection has not been demonstrated and remains uncertain.

Several studies suggested that conventional DCs were important as a source of IL-12 in *T. gondii* infection, but neither excludes macrophages nor identifies the type of DC that might be responsible for protection. One study used a lineage ablation approach in which the Diphtheria toxin receptor (DTR) was expressed under control of the *Itgax* gene promoter (encoding CD11c, referred to as CD11c-DTR mice), in order to ask whether DCs were involved in protection against infection by *T. gondii* (Liu et al., 2006). Diphtheria toxin (DT) administration in these mice caused the depletion of CD11c-expressing cells and greatly increased susceptibility to *T. gondii* infection. Enhanced susceptibility was attributed to the depletion of IL-12-producing DCs, but could also result from loss of macrophages because CD11c-DTR also depletes several subsets of splenic macrophages (Probst et al., 2005). Although transfer of wild-type DCs, but not IL-12-deficient DCs, did rescue susceptibility in DT-treated mice, this rescue does not exclude macrophages as the cell that normally provides protection against *T. gondii* infection *in vivo*. A recent study used selective expression of Cre recombinase in CD11c-expressing (*Itgax*-Cre) or Lysozyme M-expressing (*Lyz2*-Cre) cells in an attempt to exclusively delete the toll-like receptor (TLR) adaptor protein MyD88 from DCs and macrophages, respectively (Hou et al., 2011). Deletion of *Myd88* by CD11c-Cre was sufficient to decrease early IL-12 production during *T. gondii* infection and led to increased susceptibility, suggesting that IL-12 production by a CD11c-expressing cell was critical for resistance to *T. gondii* infection. However, as with the study by Liu et al. above, CD11c is expressed by certain macrophage populations, making it difficult to discern unambiguously which cell is protective *in vivo*.

A few studies have addressed the potential function of the CD8 α ⁺ DC subset in resistance to *T. gondii*. Studies of *Irf8*-deficient mice have suggested a role for the CD8 α ⁺ DC subset as a protective source of IL-12 in *T. gondii* infection (Scharton-Kersten et al., 1997a), but such studies are inconclusive because these mice harbor additional defects beyond the loss of CD8 α ⁺ DCs. *Irf8*-deficient mice lack development of both CD8 α ⁺ DCs as well as pDCs (Aliberti et al., 2003; Tsujimura et al., 2003), and additionally have defects in activation of IFN γ -inducible genes (Tamura and Ozato, 2002). Thus, the increased susceptibility of *Irf8*^{-/-} mice to *T. gondii* infection (Scharton-Kersten et al., 1997a) could result from the absence of either CD8 α ⁺ DCs or pDCs, or from a failure of IFN γ -induced effector mechanisms. Consistent with the latter, administration of IL-12 to *Irf8*^{-/-} mice produces only a partial and temporary reduction in susceptibility to *T. gondii* (Scharton-Kersten et al., 1997a). In addition, CD8 α ⁺ DCs are the major source of IL-12 after intravenous administration of STAg (Reis e Sousa et al., 1997), although the relevance of this IL-12 to protection against live *T. gondii* has not been shown. In summary, although several cell types have been shown to be capable of producing IL-12 in response to *T. gondii*, the important cell type required for *in vivo* production of IL-12 after *T. gondii* infection has not been established.

In this study, we used *Batf3*^{-/-} mice (Hildner et al., 2008) that are specifically defective in the generation of the CD8 α ⁺ DC subset to address the importance of these cells as a source of IL-12 during *T. gondii* infection. *Batf3*^{-/-} mice exhibit decreased IL-12 and IFN γ production and a dramatically increased susceptibility to *T. gondii*, dying within 9 days after infection. Furthermore, this susceptibility in *Batf3*-deficient mice was reversed by administration of IL-12. Finally, we showed that the CD8 α ⁺ DCs were the only cells within the innate immune system whose IL-12 production was required for resistance to acute *T. gondii* infection.

Results

Batf3^{-/-} mice are highly susceptible to *T. gondii* infection

We first compared the survival of wild-type and *Batf3*^{-/-} mice to infection with *T. gondii* (Figure 1). Intraperitoneal (ip) infection by tachyzoites of the type II avirulent Prugniaud (Pru) strain of *T. gondii* revealed a markedly increased susceptibility of *Batf3*^{-/-} mice relative to wild-type mice (Figure 1A). While wild-type mice were resistant to *T. gondii* infection, infection of *Batf3*^{-/-} mice was uniformly lethal in all genetic backgrounds tested and led to death within 9 to 10 days after infection. Using a *T. gondii* strain harboring a firefly luciferase transgene reporter, we observed approximately 100-fold increased parasite burden within 5 days following infection in *Batf3*-deficient mice compared to wild-type mice (Figure 1B and 1C). This exponential parasite growth continued in the *Batf3*^{-/-} mice throughout the course of infection.

To extend our findings, we challenged wild-type and *Batf3*^{-/-} mice with *T. gondii* cysts by oral gavage, which simulates the natural route of infection. Oral challenge of *Batf3*^{-/-} mice demonstrated a similar susceptibility of these animals to *T. gondii* infection, with acute lethality and a failure to control parasite replication (Figure S1A and S1B). In addition, histological analysis of the spleen and ileum revealed extensive inflammation and destruction of tissue architecture in *Batf3*^{-/-} mice 9 days after infection (Figure S1C). However, the underlying mechanism for this susceptibility is likely to be complex, and will be the focus of future studies. Specifically, gut CD103⁺ DCs are also absent in the *Batf3*^{-/-} mice (Edelson et al., 2010), and may play a role during oral infection. All other experiments in this study were performed following intraperitoneal tachyzoite challenge.

To determine if the crucial effector cytokines IL-12 and IFN γ were being produced normally in *Batf3*^{-/-} mice, we next examined the serum amounts of these cytokines. The IL-12 subunit p40, which is shared with the cytokine IL-23, is used as the readout for IL-12 in all cases, since IL-23 plays no role in acute *T. gondii* infection in the mouse (Lieberman et al., 2004). IL-12p40 concentrations in serum were markedly reduced in *Batf3*^{-/-} mice relative to wild-type mice infected with *T. gondii* (Figure 1D). In wild-type mice, serum IL-12p40 began to increase on day 3 after infection, and increased until 7 days after infection. In contrast, IL-12p40 remained at basal amounts in *Batf3*^{-/-} mice until day 5 after infection, at which point its increase was significantly reduced relative to wild-type mice for the remainder of infection. The decrease in IL-12p40 production in *Batf3*^{-/-} mice correlated with significantly reduced concentrations of serum IFN γ (Figure 1E). In wild-type mice, IFN γ production began to increase after 4 to 5 days of infection, reaching a peak at day 8. By contrast, IFN γ showed no increase in *Batf3*^{-/-} mice for 5 days after infection, and showed only a slight increase on day 7, when it was significantly reduced relative to wild-type mice.

CD8⁺ T cell priming to *T. gondii*-derived antigens is defective in *Batf3*^{-/-} mice

Since CD8 α ⁺ DCs are important for generation of virus-specific CD8⁺ effector T cells (Hildner et al., 2008), we examined T cell responses in *Batf3*^{-/-} mice after infection by *T. gondii* (Figure 2). First, we used two MHCI tetramers to measure the expansion of CD8⁺ T cells specific for peptides derived from the GRA4 and GRA6 dense granule proteins of *T. gondii* (Frickel et al., 2008). Tetramer positive CD8⁺ T cells were significantly increased 8 days after infection with *T. gondii* in the spleen of wild-type mice, but not in *Batf3*^{-/-} mice (Figure 2A). Tetramer staining in the peritoneum suggested a similar trend, although the data did not reach significance due to substantial variability in the observed response in wild-type mice (Figure 2B–2D). Total splenic CD8⁺ T cell numbers were comparable between wild-type and *Batf3*^{-/-} mice both before and after infection (Figure S2B). However, the total number of peritoneal CD8⁺ T cells appeared to be highest in infected

wild-type mice (Figure S2A), suggesting local proliferation or recruitment of activated cells, although again this increase did not reach significance as compared to *Batf3*^{-/-} numbers. In addition, using the GRA4 peptide to activate splenic antigen-specific CD8⁺ T cells harvested 8 days after infection, we observed a significant increase in peptide induced IFN γ production from wild-type CD8⁺ T cells, but not from *Batf3*^{-/-} CD8⁺ T cells (Figure 2E). Thus, *Batf3*^{-/-} mice have reduced priming of IFN γ -producing CD8⁺ T cells after infection by *T. gondii*, suggesting that CD8 α ⁺ DCs contribute to the priming of CD8⁺ T cells against this intracellular pathogen.

In summary, *Batf3*^{-/-} mice are highly susceptible to *T. gondii* infection compared with wild-type mice, and have substantially reduced IL-12 and IFN γ production during early infection (Figure 1). In addition, priming of *T. gondii*-specific CD8⁺ T cells is reduced in infected *Batf3*^{-/-} mice (Figure 2), although the rapid lethality of *T. gondii* infection in *Batf3*^{-/-} mice suggests a defect in an innate rather than adaptive immune response. To further exclude a role for *Batf3* in T cells in the acute lethality observed, we transferred wild-type purified T cells into *Rag2*-deficient mice that were either wild-type or deficient for *Batf3*. *Rag2*^{-/-} mice cannot generate T or B cells due to a failure to recombine and express the required receptors, and therefore the only T cells present in these mice will be the transferred wild-type cells. *Batf3*^{-/-}*Rag2*^{-/-} animals that were given wild-type T cells were indistinguishable from *Batf3*^{-/-} mice when examined for parasite burden after *T. gondii* infection (Figure S2C), suggesting that the defect observed in *Batf3*^{-/-} mice is restricted to the innate compartment. Therefore, we next focused on identifying the cellular source of IL-12 relevant for protection against *T. gondii* infection in wild-type mice.

CD8 α ⁺ DCs increase in early infection by *T. gondii* and are the major producers of IL-12

In uninfected wild-type mice, the CD8 α ⁺ subset of conventional DCs comprises approximately 5–10% of the total DC compartment in the spleen, depending on the mouse strain (Hildner et al., 2008). CD8 α ⁺ DCs also express several surface markers such as CD103, CD24 and DEC205 that distinguish it from the newly described CX3CR1⁺ CD8 α ⁺ DC subset that is distinct from classical CD8 α ⁺ DCs (Bar-On et al., 2010), and one of these additional markers is used in every experiment to ensure exclusion of the CX3CR1-expressing subset. The remainder of conventional DCs are distributed between those expressing high or low levels of CD11b. After infection by *T. gondii*, we observed that the percentage of CD8 α ⁺ DCs in wild-type mice increased to represent approximately 20% of the total DC compartment in the spleen by 7 days after infection (Figure 3A). By contrast, *Batf3*^{-/-} mice lacked CD8 α ⁺ DCs as previously reported (Hildner et al., 2008) and showed no increase at any time after infection. Beyond this increase in their percentage, CD8 α ⁺ DCs also increased in absolute numbers in the spleens of wild-type mice after *T. gondii* infection (Figure 3B). By contrast, CD11b⁺ DCs were present in similar numbers during all times after *T. gondii* infection in both wild-type and *Batf3*^{-/-} mice (Figure 3C and S3).

Increased numbers of CD8 α ⁺ DCs after *T. gondii* infection suggests a role in protection against this parasite. Therefore, production of IL-12p40 by various cell types was measured in wild-type and *Batf3*^{-/-} mice after infection by *T. gondii* (Figure 4). We examined day 3 after infection specifically, since we were interested in cells producing IL-12p40 early enough after infection that could control the exponential growth of *T. gondii* observed as early as day 4 in *Batf3*^{-/-} mice (Figure 1B). We used intracellular cytokine staining (ICS) to quantify IL-12p40 production by CD8 α ⁺ DCs, CD11b⁺ DCs, pDCs, inflammatory monocytes and neutrophils. The percentage of CD8 α ⁺ DCs producing IL-12p40 was increased from basal levels in uninfected mice to approximately 25–30% at day 3 after infection (Figure 4A). By contrast, the percentage of CD11b⁺ DCs that produced IL-12p40 was not significantly altered by infection, being approximately 2 to 3% in both infected and uninfected mice (Figure 4A). Furthermore, inflammatory monocytes, neutrophils and

plasmacytoid DCs displayed no induction of IL-12p40 by *T. gondii* infection (Figure 4B). Accordingly, CD8 α^+ DCs express the highest amounts of the *T. gondii* profilin sensor TLR11 as compared with a variety of immune cell types (Figure S4A), suggesting that this cell is optimally poised for sensing *T. gondii* and producing initial IL-12 during early infection. In addition, since the IL-12p40 chain is shared between the cytokines IL-12 and IL-23, we formally excluded a role for IL-23 in our system by examining CD8 α^+ DC induction of the IL-23-specific subunit p19 and the IL-12-specific subunit p35 upon infection. Uninfected and infected CD8 α^+ DCs express the IL-12p40 subunit (Figure S4C), as shown above, in conjunction with the IL-12p35 subunit (Figure S4D), but not the IL-23p19 subunit (Figure S4B), clearly showing production of IL-12 and not IL-23 by these cells. In addition, expression of IL-12p40 is significantly increased in these cells on day 3 after infection (Figure S4D). Thus, CD8 α^+ DCs are the major IL-12-producing cells in the spleen 3 days after infection by *T. gondii*.

IL-12 administration to *Batf3*^{-/-} mice restores IFN γ production and controls *T. gondii* infection

If susceptibility of *Batf3*^{-/-} mice to *T. gondii* results from decreased IL-12 production caused by the absence of CD8 α^+ DCs, then administration of IL-12 to *Batf3*^{-/-} mice should restore their resistance to infection. Administration of recombinant murine IL-12 to wild-type mice had no impact on their susceptibility to infection by *T. gondii* (Figure 5A). In contrast, administration of IL-12 to *Batf3*^{-/-} mice during the first 5 days of infection dramatically reversed their susceptibility, promoting their survival after infection for more than 60 days. Moreover, IL-12 treatment of *Batf3*^{-/-} mice reduced their pathogen burden compared to untreated *Batf3*^{-/-} mice, bringing parasite loads to levels in wild-type mice (Figure 5B and 5C).

Since reduced IL-12 in *Batf3*^{-/-} mice may cause susceptibility to *T. gondii* by lowering early IFN γ production, we asked whether IL-12 administration to *Batf3*^{-/-} mice also restored normal IFN γ production during infection (Figure 5D–5G). IL-12 administration to wild-type mice did not influence serum IFN γ concentrations at day 4 after infection (Figure 5D). However, IL-12 administration to *Batf3*^{-/-} mice significantly increased serum IFN γ on day 4, which approximated amounts found in infected wild-type mice. The IFN γ induced by IL-12 in *Batf3*^{-/-} mice appeared to arise from several cell types (Figure 5E–5G and S5A–S5C). NK, CD4⁺ and CD8⁺ T cells from infected wild-type mice produced IFN γ by ICS on day 3 when examined immediately *ex vivo*, but NK, CD4⁺ and CD8⁺ T cells from infected *Batf3*^{-/-} mice were devoid of IFN γ at this time. However, administration of IL-12 to *Batf3*^{-/-} mice infected with *T. gondii* substantially restored IFN γ production by all three cell types. In summary, IL-12 administration to *Batf3*^{-/-} mice reverses their susceptibility to *T. gondii* infection, decreases pathogen burden, and increases IFN γ production by natural killer cells and T lymphocytes.

CD8 α^+ DCs are the only cell whose IL-12 production is required to control acute *T. gondii* infection

The fact that CD8 α^+ DCs are a major source of IL-12 during acute *T. gondii* infection does not prove that they are the only source of IL-12 capable of controlling infection, and their requirement for protection against acute infection may derive from different, unknown functions. To test whether IL-12 production by CD8 α^+ DCs is relevant for resistance to acute *T. gondii* infection, we generated mixed chimeras using bone marrow (BM) derived from *Il12a*^{-/-} (encoding IL-12p35 subunit) and *Batf3*^{-/-} mice. CD8 α^+ DCs can develop from *Il12a*^{-/-} BM, but not *Batf3*^{-/-} BM. This protocol allows the generation of chimeras in which CD8 α^+ DCs now develop but are unable to produce IL-12, while all other immune

cell types can produce IL-12. If CD8 α^+ DCs are solely required for providing an early source of IL-12, then the mixed chimeras will remain susceptible to infection.

For this experiment, several other chimeras are necessary as controls. We generated chimeras receiving only wild-type, *Batf3*^{-/-}, or *Il12a*^{-/-} BM, as well as mixed chimeras receiving wild-type BM with either *Batf3*^{-/-} or *Il12a*^{-/-} BM (Figure 6 and S6A). Chimeras of all 6 types were infected with *T. gondii* and analyzed along with non-chimera controls for survival and parasite burden. First, chimeras reconstituted with wild-type BM controlled parasite numbers as expected, with burden equivalent to wild-type non-chimeric mice (Figure 6B and 6C). The majority of these mice also survived acute infection (Figure 6A). Chimeras reconstituted either with *Batf3*^{-/-} or *Il12a*^{-/-} BM succumbed to acute infection as expected and showed high parasite burdens, each approximately 100-fold higher than wild-type, reflecting the phenotype of the respective mutant non-chimeric mice (Figure 6A–6C and S6A).

We next examined mixed bone marrow chimeras. Mixed chimeras reconstituted with wild-type plus *Batf3*^{-/-} BM or *Il12a*^{-/-} BM showed low parasite burdens, equivalent to wild-type mice and chimeras reconstituted with wild-type BM (Figure 6B, 6C and S6A). In both of these mixed chimeras, only half of the cells would harbor a defect, and the other half would be normal. Thus, a half cell complement of normal cells appears sufficient for normal control of parasite burden.

Finally, we analyzed chimeras reconstituted with a mixture of *Batf3*^{-/-} and *Il12a*^{-/-} BM (Figure 6 and S6A). In these chimeras, CD8 α^+ DCs develop only from *Il12a*^{-/-} BM, whereas all other cells develop from both IL-12-sufficient and *Il12a*^{-/-} BM. Thus, in these chimeras, the CD8 α^+ DCs uniformly lack the capacity to produce IL-12, whereas all other cell types retain the capacity to produce IL-12. These mixed chimeras are highly susceptible to infection and have extremely high parasite burden, comparable to levels in *Batf3*^{-/-} mice (Figure 6A–6C and S6A). These results indicate that the CD8 α^+ DCs are the only cell whose IL-12 production is sufficient for controlling parasite burden and maintaining resistance to acute *T. gondii* infection.

Discussion

The present study identifies a second critical activity for the CD8 α^+ DC subset beyond its recognized role in priming CD8 $^+$ T cell responses to viruses. Previously, we demonstrated that the CD8 α^+ DC was critical in promoting effective CTL responses against West Nile virus, and was crucial in that setting for cross-presentation of virus-derived antigens involved in immune activation (Hildner et al., 2008). Additionally, priming of Sendai virus-specific CTLs has also been shown to be dependent on the peripheral cross-presenting CD103 $^+$ DC which is also absent in the *Batf3*-deficient mice (Edelson et al., 2010). Here we show that priming of CD8 $^+$ T cells to endogenous *T. gondii* antigen is also defective in *Batf3*-deficient mice early after infection. Additionally, we demonstrate that the same DC subset provides a critical but distinct function by acting as an important early sensor of infection by *T. gondii*. The inability of mixed chimeras generated from bone marrow of *Il12a*-deficient and *Batf3*-deficient mice to control *T. gondii* infection demonstrates that the CD8 α^+ DC is the only cell whose IL-12 production significantly contributes to reducing pathogen burden during acute infection. Thus, in each of these pathogen settings, the CD8 α^+ dendritic cell is unique in its provision of effective defense mechanisms, but the mechanisms by which this cell mediates defenses are different.

Mice lacking *Batf3* show a very selective elimination of the subset of DCs characterized by the selective expression of CD8 α , CD103, DEC205, CLEC9a, and Langerin (Hildner et al.,

2008; Edelson et al., 2010; Sancho et al., 2009). In uninfected mice, DCs of this subset comprise between 5–10% of the total DC compartment, and are distributed both to the secondary lymphoid organs, including spleen and lymph nodes, where they express CD8 α as a marker, as well as to various peripheral tissues, such as the dermis, lung, and lamina propria, where they lack CD8 α but express the remaining markers (Edelson et al., 2010). *Batf3*-deficient mice do not exhibit any apparent global immunodeficiency, being generally healthy in the absence of overt infection, and generating essentially normal CD4⁺ T cell responses and antibody responses to viruses including West Nile virus (Hildner et al., 2008). Since control of many pathogens can be mediated by one of several immune effector mechanisms, the intact CD4⁺ T cell responses and antibody responses in *Batf3*-deficient mice would appear to be responsible for the overall general health. However, certain immune responses appear to be critically dependent on an intact cross-presentation pathway, such as the rejection of syngeneic fibrosarcoma, which is completely defective in *Batf3*-deficient mice (Hildner et al., 2008). Until now, studies of *Batf3*-deficient mice have largely focused on features of the adaptive immune response rather than examining innate immunity. Therefore, the present study identifies a critical role uniquely for the CD8 α ⁺ DC in innate immune responses against pathogens *in vivo*.

The role of CD8 α ⁺ DCs in protection against *T. gondii* infection was previously suggested through the observation that this subset was the major cell type to produce IL-12 in response to intravenous administration of *T. gondii* antigen STAg (Reis e Sousa et al., 1997). Furthermore, CD8 α ⁺ DCs express TLR11 at much higher levels than CD8 α ⁻ DCs (Yarovinsky et al., 2005), neutrophils, and monocytes. However, pDCs also express TLR11 (Pepper et al., 2008), so that the correlation between sensitivity to activation by *T. gondii* does not exclusively identify the CD8 α ⁺ DC as the main responder. Thus, no clear evidence previously was able to uniquely identify the CD8 α ⁺ DC as a cell type required for controlling *T. gondii* infection *in vivo*. In addition, while *Tlr11*-deficient mice show impaired IL-12 production following infection by *T. gondii* (Yarovinsky et al., 2005), these mice only show a modest change in susceptibility compared to the dramatic increase seen in *Myd88*-deficient mice (Scanga et al., 2002), implying that additional sensors for *T. gondii* infection may exist. Our data strongly demonstrate that the CD8 α ⁺ DC is the main cell induced to produce IL-12 after acute challenge with *T. gondii* tachyzoites, which agrees with selective expression of TLR11 and potentially other uncharacterized *T. gondii*-specific sensors by this cell type. Nonetheless, other DC subsets may dominate in infections initiated by *T. gondii* cysts in the peritoneal cavity (data not shown).

It is unclear what advantage the immune system gains from limiting either cross-presentation or the production of IL-12 during infection to a single subset of dendritic cells. On the one hand, if cross-presentation is an important requirement for generation of CD8⁺ T cell responses against intracellular pathogens, one might reason that allowing all dendritic cells to exercise this function *in vivo* would better suite robust CTL responses. On the other hand, it is unclear what advantage the immune system gains by restricting IL-12 production in response to *T. gondii* infection to a single subset. CD8 α ⁺ DCs, which possess both peripheral and lymphoid resident populations, clearly express a unique pattern of innate sensors that distinguish these cells from other populations of conventional DCs and macrophage and/or monocytes subsets. Conceivably, restricting production of IL-12 to this unique subset could act to limit immunopathology that may derive from overproduction of IL-12 during infection. An example of the importance of this balance between immune activation and control is seen in the *Il10*-deficient mice, which succumb to *T. gondii* infection due to immunopathology caused by overproduction of IL-12 (Gazzinelli et al., 1996). Whatever the reasons, the present results clearly demonstrate a second critical function *in vivo* for the CD8 α ⁺ DC, in which selective activation of CD8 α ⁺ DCs and their

subsequent production of IL-12 is a major pathway leading to early IFN γ -mediated control of *Toxoplasma gondii* infection.

Experimental Procedures

Mice

Wild-type 129S6/SvEv, BALB/c, C57BL/6, and B6.SJL mice were originally purchased from Taconic and then bred in-house for experimental use. C57BL/6 *Rag2*^{-/-} mice were purchased from Taconic. *Il12a*^{-/-} mice were purchased from Jackson Labs on both C57BL/6 and BALB/c backgrounds. Additional experimental C57BL/6 and B6.SJL mice were also purchased from Jackson Labs. Some experiments on the BALB/c background were done using C.Cg-*Foxp3*^{tm2Tch/J} purchased from Jackson Labs that express an IRES-EGFP downstream of the *Foxp3* gene; these mice were used as wild-type controls. *Batf3*^{-/-} mice were previously generated in our laboratory (Hildner et al., 2008) on a 129S6/SvEv background, and subsequently backcrossed for 10 generations onto both C57BL/6 and BALB/c backgrounds. Mice were age and sex-matched for each experiment, and were generally between 8–15 weeks old. All mice were maintained under specific-pathogen-free conditions according to institutional guidelines and with protocols approved by the Animal Studies Committee of Washington University.

Parasites and infections

The type II Prugniaud strain of *T. gondii* expressing a firefly luciferase and GFP transgene (PRU-FLuc-GFP) (provided by J. Boothroyd, Stanford University, Palo Alto, CA) was used in all tachyzoite experiments. The parasites were grown in culture in human foreskin fibroblasts as previously described (Robben et al., 2004). For infections, freshly egressed parasites were filtered, counted, and injected intraperitoneally into mice. C57BL/6, 129S6/SvEv, and BALB/c mice were infected with 100, 200, and 1,000 tachyzoites, respectively, for most experiments. BALB/c mice used for tetramer studies were infected with 5,000 tachyzoites. BALB/c bone marrow chimeras and controls were infected with 100 tachyzoites.

Cell preparation

For all experiments except tetramer analysis, spleens were digested in 5mL Iscove's Modified Dulbecco's Media (IMDM, Invitrogen) containing 10% fetal calf serum (HyClone) with 250 μ g/mL collagenase B (Roche) and 30 U/mL DNase I (Sigma-Aldrich) for 1 hour at 37 degrees with agitation using stir-bars. For experiments analyzing intracellular cytokines, brefeldin A was added at 1 μ g/mL during collagenase B and DNase I treatment, after which the cells were incubated for an additional 3 hours in IMDM with brefeldin A. Red blood cells were lysed by incubation in ACK lysis buffer. Cells were filtered through 80- μ m strainers and counted on an analyzer (Vi-CELL, Beckman Coulter). 1–5 \times 10⁶ cells were stained for flow cytometric analysis.

For T cell analysis using tetramers, spleens were disrupted in 2mL ACK lysis buffer, filtered through 80- μ m strainers and counted on a Vi-CELL analyzer. 1–3 \times 10⁶ cells were stained for flow cytometric analysis.

For analysis of peritoneal cells, a peritoneal lavage was performed with 10mL Dulbecco's PBS (DPBS). Harvested cells were lysed in ACK buffer, filtered, counted, and stained for flow cytometry.

Flow cytometry

Cells were incubated for 5 minutes at 4 degrees with Fc Block (clone 2.4G2, BD) in FACS buffer (DPBS + 0.5% BSA + 2mM EDTA). Dead cells were excluded using LIVE/DEAD Aqua Fixable Dead Cell Stain Kit (Invitrogen). Surface staining was done for 20 minutes at 4 degrees in FACS buffer. For tetramer staining, cells were incubated in the presence of tetramer and surface antibodies for 45 minutes at 4 degrees. Absolute cell numbers were calculated using the total cell count multiplied successively by the percentages for the appropriate gates obtained through flow cytometry. Cells were analyzed on a BD FACSCantoII flow cytometer and data analyzed using FlowJo software (Tree star, Inc.).

Intracellular Cytokine Staining

For intracellular cytokine staining, cells were first surface stained, then fixed in 2% paraformaldehyde for 15 minutes at room temperature. Cells were then re-suspended in permeabilization buffer (DPBS + 0.1% BSA + 0.5% saponin) and stained with anti-IL-12p40 or anti-IFN γ for 30 minutes at 4 degrees.

In vitro T cell re-stimulation

4×10^6 splenocytes from day 8 infected mice were incubated overnight in 100 μ L cIMDM with 100 μ g/mL GRA4 peptide (SPMNGGYM). Brefeldin A at 1 μ g/mL was added during the last 4 hours of incubation. Cells were then harvested and analyzed for IFN γ production using the intracellular cytokine staining protocol described above.

Luciferase imaging

Imaging was done as previously described (Saeij et al., 2005). Briefly, mice were given intraperitoneal injections of D-Luciferin (Biosynth AG, Switzerland) at 150mg/kg and allowed to remain active for 5 minutes. Animals were then anesthetized with 2% isoflurane for 5 minutes, and then imaged using a Xenogen IVIS 200 machine (Caliper Life Sciences). Data was analyzed using the Living Image software (Caliper Life Sciences).

ELISA/CBA

IL-12p40 concentration was measured from serum samples using the Mouse IL-12p40 OptEIA ELISA set (BD Bioscience). IFN γ serum concentration was measured using the BD CBA Mouse Inflammation Kit (BD Biosciences).

Administration of IL-12

Recombinant murine IL-12 (Peprotech) was resuspended in pyrogen-free saline at a concentration of 2.5 μ g/mL, aliquoted and frozen at -80 degrees. Mice were injected ip with 0.5 μ g of IL-12 on days 0, 1, 2, 3, and 4 after infection.

BM Chimera generation

This experiment was performed once on mice on the C57BL/6 background, and once on mice on the BALB/c background. Bone marrow from femurs and tibias were harvested, red blood cells lysed in ACK lysis buffer, filtered through 80- μ m strainers, and counted using the Vi-CELL analyzer (Vi-CELL, Beckman Coulter). Recipient mice were irradiated with 800 (BALB/c) or 1,200 (C57BL/6) rads of whole body irradiation. In the experiment using C57BL/6 mice, all recipients were WT C57BL/6 or B6.SJL. In the experiment using BALB/c mice, WT recipients were used for the WT donor BM condition, while *Batf3*^{-/-} recipients were used for the *Batf3*^{-/-}, WT + *Batf3*^{-/-}, and *Il12a*^{-/-} + *Batf3*^{-/-} donor BM conditions. The following day after irradiation, the recipients were injected intravenously with 2–4 million bone marrow cells from either a single donor or a 1:1 mixture from two donors.

Mice were allowed to re-constitute for 10 (C57BL/6) to 18 (BALB/c) weeks after transfer, and subsequently bled to determine chimerism. In experiments using C57BL/6 mice, the congenic markers CD45.1 and CD45.2 were used to determine percent chimerism using flow cytometry. In experiments using BALB/c mice, male/female donors were mixed to allow for analysis of chimerism using the Y-chromosome. Peripheral blood from chimeras was lysed for genomic DNA and analyzed by quantitative real time PCR for the presence of the gene *Zfy1* on the Y-chromosome using the following primers: *Zfy1* (encoding zinc finger protein 1) *Zfy1*-forward, 5'-GCGTATCCTCATAAATGTGAC-3', and *Zfy1*-reverse, 5'-CATCTCTTACTTGAATGG-3'. *Rag2* (encoding recombination activation gene 2) was used as a normalization control, *Rag2*-forward, 5'-GGGAGGACACTCACTTGCCAGTA-3', and *Rag2*-reverse, 5'-AGTCAGGAGTCTCCATCTCACTGA-3'. Known mixtures of male-to-female DNA were used to generate a standard curve (100, 60, 50 and 40% male DNA), and to determine the percent of male DNA per sample.

Statistics

For analyses of survival data the log-rank test was used. For analyses of all other data, an unpaired, two-tailed Student's *t* test with a 95% confidence interval was used (Prism; GraphPad Software, Inc.). All data are represented as means \pm SD.

Highlights

- *Batf3*^{-/-} mice missing CD8 α ⁺ DCs succumb to *Toxoplasma gondii* tachyzoite infection
- *Batf3*^{-/-} mice have reduced amounts of IL-12 and IFN γ after infection
- IL-12 restores IFN γ and rescues survival in infected *Batf3*^{-/-} mice
- CD8 α ⁺ DCs are the only critical source of IL-12 during *T. gondii* infection *in vivo*

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Howard Hughes Medical Institute (K.M. Murphy), the American Heart Association Midwest Affiliate Predoctoral Fellowship Program (M. Mashayekhi), and AI059176 (L.D. Sibley).

References

- Aliberti J, Schulz O, Pennington DJ, Tsujimura H, Sousa Reis E, Ozato K, Sher A. Essential role for ICSBP in the *in vivo* development of murine CD8 α ⁺ dendritic cells. *Blood*. 2003; 101:305–310. [PubMed: 12393690]
- Bar-On L, Birnberg T, Lewis KL, Edelson BT, Bruder D, Hildner K, Buer J, Murphy KM, Reizis B, Jung S. CX3CR1⁺ CD8 α ⁺ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. *Proc. Natl. Acad. Sci U. S A*. 2010; 107:14745–14750. [PubMed: 20679228]
- Bliss SK, Butcher BA, Denkers EY. Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection. *J Immunol*. 2000; 165:4515–4521. [PubMed: 11035091]
- Bliss SK, Gavrilescu LC, Alcaraz A, Denkers EY. Neutrophil depletion during *Toxoplasma gondii* infection leads to impaired immunity and lethal systemic pathology. *Infect. Immun*. 2001; 69:4898–4905. [PubMed: 11447166]

- Bliss SK, Zhang Y, Denkers EY. Murine neutrophil stimulation by *Toxoplasma gondii* antigen drives high level production of IFN-gamma-independent IL-12. *J Immunol.* 1999; 163:2081–2088. [PubMed: 10438947]
- Dunay IR, Damatta RA, Fux B, Presti R, Greco S, Colonna M, Sibley LD. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen *Toxoplasma gondii*. *Immunity.* 2008; 29:306–317. [PubMed: 18691912]
- Dunay IR, Fuchs A, Sibley LD. Inflammatory monocytes but not neutrophils are necessary to control infection with *Toxoplasma gondii* in mice. *Infect. Immun.* 2010; 78:1564–1570. [PubMed: 20145099]
- Edelson BT, Wumesh KC, Juang R, Kohyama M, Benoit LA, Klekotka PA, Moon C, Albring JC, Ise W, Michael DG, Bhattacharya D, Stappenbeck TS, Holtzman MJ, Sung SSSJ, Murphy TL, Hildner K, Murphy KM. Peripheral CD103(+) dendritic cells form a unified subset developmentally related to CD8 alpha(+) conventional dendritic cells. *J. Exp. Med.* 2010; 207:823–836. [PubMed: 20351058]
- Frickel EM, Sahoo N, Hopp J, Gubbels MJ, Craver MP, Knoll LJ, Ploegh HL, Grotenbreg GM. Parasite stage-specific recognition of endogenous *Toxoplasma gondii*-derived CD8+ T cell epitopes. *J Infect. Dis.* 2008; 198:1625–1633. [PubMed: 18922097]
- Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. *Proc. Natl. Acad. Sci U. S A.* 1993; 90:6115–6119. [PubMed: 8100999]
- Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with *Toxoplasma gondii*. *J Immunol.* 1994; 153:2533–2543. [PubMed: 7915739]
- Gazzinelli RT, Wysocka M, Hieny S, Scharon-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A. In the absence of endogenous IL-10, mice acutely infected with *Toxoplasma gondii* succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. *J Immunol.* 1996; 157:798–805. [PubMed: 8752931]
- Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. *Science.* 2008; 322:1097–1100. [PubMed: 19008445]
- Hou B, Benson A, Kuzmich L, DeFranco AL, Yarovinsky F. Critical coordination of innate immune defense against *Toxoplasma gondii* by dendritic cells responding via their Toll-like receptors. *Proc. Natl. Acad. Sci U. S A.* 2011; 108:278–283. [PubMed: 21173242]
- Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, Hunter CA. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. *J Immunol.* 2004; 173:1887–1893. [PubMed: 15265921]
- Liu CH, Fan YT, Dias A, Esper L, Corn RA, Bafica A, Machado FS, Aliberti J. Cutting edge: dendritic cells are essential for in vivo IL-12 production and development of resistance against *Toxoplasma gondii* infection in mice 1. *J Immunol.* 2006; 177:31–35. [PubMed: 16785494]
- Mordue DG, Sibley LD. A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis. *J Leukoc. Biol.* 2003; 74:1015–1025. [PubMed: 12972511]
- Pepper M, Dzierszinski F, Wilson E, Tait E, Fang Q, Yarovinsky F, Laufer TM, Roos D, Hunter CA. Plasmacytoid dendritic cells are activated by *Toxoplasma gondii* to present antigen and produce cytokines. *J Immunol.* 2008; 180:6229–6236. [PubMed: 18424745]
- Probst HC, Tschannen K, Odermatt B, Schwendener R, Zinkernagel RM, Van Den BM. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. *Clin. Exp. Immunol.* 2005; 141:398–404. [PubMed: 16045728]
- Reis e Sousa C, Hieny S, Scharon-Kersten T, Jankovic D, Charest H, Germain RN, Sher A. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. *J. Exp. Med.* 1997; 186:1819–1829. [see comments]. [PubMed: 9382881]

- Robben PM, Mordue DG, Truscott SM, Takeda K, Akira S, Sibley LD. Production of IL-12 by macrophages infected with *Toxoplasma gondii* depends on the parasite genotype. *J Immunol.* 2004; 172:3686–3694. [PubMed: 15004172]
- Saeij JP, Boyle JP, Grigg ME, Arrizabalaga G, Boothroyd JC. Bioluminescence imaging of *Toxoplasma gondii* infection in living mice reveals dramatic differences between strains. *Infect. Immun.* 2005; 73:695–702. [PubMed: 15664907]
- Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, Rosewell I, Sousa Reis E. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. *Nature.* 2009; 458:899–903. [PubMed: 19219027]
- Sayles PC, Johnson LL. Exacerbation of toxoplasmosis in neutrophil-depleted mice. *Nat Immun.* 1996; 15:249–258. [PubMed: 9390274]
- Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, Denkers EY, Medzhitov R, Sher A. Cutting edge: MyD88 is required for resistance to *Toxoplasma gondii* infection and regulates parasite-induced IL-12 production by dendritic cells. *J Immunol.* 2002; 168:5997–6001. [PubMed: 12055206]
- Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. *J. Exp. Med.* 1997a; 186:1523–1534. [PubMed: 9348310]
- Scharton-Kersten TM, Yap G, Magram J, Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen *Toxoplasma gondii*. *J Exp. Med.* 1997b; 185:1261–1273. [PubMed: 9104813]
- Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol.* 2006; 7:311–317. [PubMed: 16462739]
- Tamura T, Ozato K. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. *J Interferon Cytokine Res.* 2002; 22:145–152. [PubMed: 11846985]
- Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. *J Immunol.* 2003; 170:1131–1135. [PubMed: 12538667]
- Yap GS, Shaw MH, Ling Y, Sher A. Genetic analysis of host resistance to intracellular pathogens: lessons from studies of *Toxoplasma gondii* infection. *Microbes Infect.* 2006; 8:1174–1178. [PubMed: 16513380]
- Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, Hieny S, Sutterwala FS, Flavell RA, Ghosh S, Sher A. TLR11 activation of dendritic cells by a protozoan profilin-like protein. *Science.* 2005; 308:1626–1629. [PubMed: 15860593]




Figure 1. *Batf3*^{-/-} mice rapidly succumb to infection with an avirulent strain of *Toxoplasma gondii*

Mice were infected with *T. gondii*, monitored for survival (A) and parasite burden (B and C), and bled to measure serum cytokines (D and E). (A) Combined survival data from infected C56BL/6, 129S6/SvEV and BALB/c wild-type (solid line, n=30) and *Batf3*^{-/-} (dashed line, n=29) mice from 8 independent experiments. (B) Infected wild-type (squares) and *Batf3*^{-/-} (triangles) mice underwent whole body *in vivo* imaging throughout the course of infection to measure bioluminescence. Data shown is combined parasite burden from infected 129S6/SvEV mice from 2 independent experiments (n=5–8 at each time-point, representative of 6 independent experiments). (C) Representative bioluminescence images of infected 129S6/SvEV mice throughout the course of infection. (D and E) Infected 129S6/SvEV wild-type (squares) and *Batf3*^{-/-} (triangles) mice were bled at various time-points after infection, and serum analyzed for cytokine concentrations. Data represents combined serum concentrations of IL-12p40 (D) and IFN γ (E) through the course of infection from 2–

3 independent experiments (n=3–5 at each time-point). (B, D, E) Data are represented as mean \pm standard deviation. *: $0.01 < P < 0.05$, **: $0.001 < P < 0.01$, ***: $P < 0.001$.




Figure 2. CD8⁺ T cell priming to *T. gondii* is defective in *Batf3*-deficient mice

BALB/c wild-type and *Batf3*^{-/-} mice were infected with *T. gondii*, sacrificed on day 8 after infection, and analyzed for CD8⁺ T cell priming by tetramer staining *ex vivo* (A–D) and intracellular cytokine staining following peptide re-stimulation *in vitro* (E). (A) Representative plots of L^d-GRA4 and L^d-GRA6 tetramer staining in the peritoneum, with percentage of total peritoneal cells that are tetramer positive shown. (B–D) Absolute numbers of CD8⁺ tetramer-positive cells in the peritoneum (B and C) or spleen (D) specific for GRA4 (B and D) or GRA6 (C) on day 8 after infection (n=3, representative of 2 independent experiments). (E) Absolute numbers of IFN γ -positive CD8⁺ T cells as measured by intracellular cytokine staining after overnight re-stimulation of whole splenocytes with the GRA4 peptide (n=5). (B–E) Data are represented as mean \pm standard deviation. Not significant (ns): P>0.05, *: 0.01<P<0.05.




Figure 3. Splenic CD8 α ⁺ dendritic cells expand after *T. gondii* infection in wild-type mice
 129S6/SvEV wild-type and *Batf3*^{-/-} mice were infected with *T. gondii*, sacrificed on days 0, 3, 5 and 7 after infection, and analyzed for changes in dendritic cell subsets by flow cytometry. (A) Representative flow cytometry plots gated on Aqua-negative, MHCII⁺, CD11c⁺ conventional dendritic cells. (B and C) Absolute numbers of CD8 α ⁺ CD103⁺ DCs (B) and CD11b⁺ DCs (C) in the spleen of wild-type (black bars) and *Batf3*^{-/-} (white bars) mice throughout the course of infection (n=3, representative of 2 independent experiments). Data are represented as mean \pm standard deviation.




Figure 4. CD8α⁺ dendritic cells are the major producers of IL-12 after *T. gondii* infection in wild-type mice

129S6/SvEV wild-type and *Batf3*^{-/-} mice were infected with *T. gondii*, sacrificed on day 3 after infection, and analyzed for the cellular source of IL-12 by intracellular cytokine staining. (A) Representative flow cytometry plots gated on MHCII⁺ CD11c⁺ expressing CD11b⁺ DCs or CD8α⁺ DEC205⁺ DCs. (B) Representative flow cytometry plots gated on Ly-6G⁺ CD11b⁺ neutrophils, Ly-6G⁻ Ly-6C⁺ CD11b⁺ inflammatory monocytes, or CD11c⁺ Bst2⁺ plasmacytoid DCs. (n=3, representative of 3 independent experiments).




Figure 5. Administration of IL-12 rescues *Batf3*-deficient mice during *T. gondii* infection
 129S6/SvEV mice were infected with *T. gondii* and injected with saline or 0.5 μ g of recombinant murine IL-12 on days 0, 1, 2, 3, and 4 after infection. (A) Survival data from infected mice (WT: solid black line; WT + IL-12: solid red line; *Batf3*^{-/-}: dashed black line; *Batf3*^{-/-} + IL-12: dashed red line) (n=3–5, representative of 3 independent experiments). (B) Combined parasite burden from whole body *in vivo* bioluminescence imaging of infected mice (WT: black squares; WT + IL-12: red squares; *Batf3*^{-/-}: black triangles; *Batf3*^{-/-} + IL-12: red triangles) from 2 independent experiments (n=3–8 at each time-point, representative of 4 independent experiments). Data are represented as mean \pm standard deviation. (C) Representative bioluminescence images of infected mice throughout the

course of infection. (D) Serum concentrations of IFN γ on day 4 after infection (n=4–5). (E–G) Absolute numbers of IFN γ -positive NK (E), CD4⁺ T (F), and CD8⁺ T (G) cells in the spleen directly *ex vivo* on day 3 after infection as measured by intracellular cytokine staining (n=3). (D–G) Horizontal lines represent the geometric mean. Not significant (ns): P>0.05, *: 0.01<P<0.05, **: 0.001<P<0.01, ***: P<0.001.




Figure 6. CD8 α^+ dendritic cells are the only cells whose IL-12 production is protective against acute *T. gondii* infection

BALB/c chimeras and control non-chimeric mice were infected with *T. gondii* and monitored for survival (A) and parasite burden (B–C). (A) Survival data from non-chimeric wild-type (black line) and *Batf3*^{-/-} (red line) mice were compared to lethally irradiated recipients which received only wild-type (purple line) or *Batf3*^{-/-} (green line) BM, or a 1:1 mixture of wild-type with *Batf3*^{-/-} BM (orange line) or *Il12a*^{-/-} with *Batf3*^{-/-} BM (blue line) (n=5–6, representative of 2 independent experiments). Parasite burden (B) and representative images (C) on day 7 after infection from the groups in (A). (B) Horizontal lines represent the geometric mean. **: 0.001 < P < 0.01, ***: P < 0.001.